0 224

Cited 42 times in

Relationship of serum TWEAK level to cytokine level, disease activity, and response to anti-TNF treatment in patients with rheumatoid arthritis

Authors
 M-C Park  ;  S-J Jung  ;  Y-B Park  ;  S-K Lee 
Citation
 SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, Vol.37(3) : 173-178, 2008 
Journal Title
 SCANDINAVIAN JOURNAL OF RHEUMATOLOGY 
ISSN
 0300-9742 
Issue Date
2008
MeSH
Adult ; Antirheumatic Agents/therapeutic use ; Arthritis, Rheumatoid/blood* ; Arthritis, Rheumatoid/drug therapy ; Case-Control Studies ; Cytokine TWEAK ; Etanercept ; Female ; Humans ; Immunoglobulin G/therapeutic use ; Interleukin-6/blood* ; Male ; Middle Aged ; Receptors, Tumor Necrosis Factor/therapeutic use ; Severity of Illness Index ; Spondylitis, Ankylosing/blood* ; Spondylitis, Ankylosing/drug therapy ; Treatment Outcome ; Tumor Necrosis Factor-alpha/blood* ; Tumor Necrosis Factors/blood*
Keywords
Adult ; Antirheumatic Agents/therapeutic use ; Arthritis, Rheumatoid/blood* ; Arthritis, Rheumatoid/drug therapy ; Case-Control Studies ; Cytokine TWEAK ; Etanercept ; Female ; Humans ; Immunoglobulin G/therapeutic use ; Interleukin-6/blood* ; Male ; Middle Aged ; Receptors, Tumor Necrosis Factor/therapeutic use ; Severity of Illness Index ; Spondylitis, Ankylosing/blood* ; Spondylitis, Ankylosing/drug therapy ; Treatment Outcome ; Tumor Necrosis Factor-alpha/blood* ; Tumor Necrosis Factors/blood*
Abstract
OBJECTIVES: To determine the serum concentration of tumour necrosis factor (TNF)-related weak inducer of apoptosis (TWEAK) in patients with rheumatoid arthritis (RA) and to investigate the relationship between TWEAK level and disease activity, proinflammatory cytokine levels, and response to anti-TNF treatment. METHODS: Serum samples from 40 patients with RA, 40 patients with ankylosing spondylitis (AS), and 40 healthy subjects were collected. Serum samples from 26 patients with RA who received etanercept treatment were also collected in the 12th week of etanercept therapy. Serum TWEAK, TNFalpha, and interleukin (IL)-6 levels were determined by enzyme-linked immunosorbent assay (ELISA), and disease activity of RA was assessed according to the 28-joint count Disease Activity Score (DAS28). RESULTS: Patients with RA had significantly higher serum levels of TWEAK, TNFalpha, and IL-6 compared with controls (p<0.05). Patients with AS also had significantly higher serum levels of TNFalpha and IL-6 (p<0.05), but their serum TWEAK levels were not different from those of the controls. In patients with RA, serum TWEAK levels correlated with DAS28 (r(2) = 0.452, p = 0.012) and TNFalpha levels (r(2) = 0.653, p<0.001) but not with IL-6 levels. Among RA patients who were treated with etanercept, responders showed a significant decrease in serum TWEAK levels at the 12th week of treatment, whereas TWEAK levels in nonresponders were not different from their baseline levels. CONCLUSIONS: Serum levels of TWEAK were significantly elevated in patients with RA, and reflected disease activity and short-term response to etanercept treatment.
Full Text
http://informahealthcare.com/doi/abs/10.1080/03009740801898608
DOI
10.1080/03009740801898608
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
Yonsei Authors
Park, Min Chan(박민찬) ORCID logo https://orcid.org/0000-0003-1189-7637
Park, Yong Beom(박용범)
Lee, Soo Kon(이수곤)
Jeong, Su Jin(정수진) ORCID logo https://orcid.org/0000-0003-4025-4542
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/108140
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse